Uncategorized

Inspectors found 111 open tickets for software defects categorized as catastrophic or severe patient harm. Several safety complaints were also listed that BD didn’t report within the required timeframe.

IPOs in medtech have been sparse, but some analysts said improving market conditions could support a revival of offerings in 2025.

Novo Nordisk executives set a high bar for itself when it projected CagriSema could achieve 25% weight loss. When the GLP-1 combo didn’t hit that mark, investors reeled.

From challenging market leaders to the growing influence of artificial intelligence, medical device executives had a lot to discuss this year. Check out MedTech Dive’s top Q&As of 2024.

Galectin’s shares tanked in premarket trading Friday after the biotech revealed its lead asset missed the primary endpoint for its Phase IIb/III trial for patients with a type of liver cirrhosis.

The breach is the third largest reported to a portal managed by federal regulators this year.

First approved in 2021, Jemperli has now become a cornerstone of GSK’s cancer business, earning more than $160 million in the third quarter.

Un nuevo estudio identifica diferencias sutiles en la forma de la cara que podrían estar relacionadas con la esquizofrenia y el trastorno bipolar. Según las conclusiones, estos patrones faciales estarían asociados con algunas medidas del córtex cerebral.   El estud …

En el centro de esta fotografía, tomada desde el espacio el 23 de octubre de 2024 por la nave MRO (Mars Reconnaissance Orbiter) de la NASA, en órbita a Marte desde 2006, puede vislumbrarse a la sonda espacial InSight posada en un punto del suelo marciano, donde aterrizó en 2018. …

Investors appeared disappointed by CagriSema’s Phase III readout, which showed weight loss that fell short of Novo Nordisk’s prior projections for the therapy. Meanwhile, Eli Lilly’s stock rose on the news.